NCT01954030 2016-02-19Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab FailureDuke UniversityPhase 1 Terminated17 enrolled
NCT00458731 2014-02-19Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic AstrocytomaNational Cancer Institute (NCI)Phase 1 Completed57 enrolled
NCT00734890 2012-03-16Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or LymphomaNational Institutes of Health Clinical Center (CC)Phase 1 Completed18 enrolled